GALLEIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H12O7
Molecular Weight	364.3051
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=C2C(OC3=C(O)C(O)=CC=C3C24OC(=O)C5=CC=CC=C45)=C1O

InChI

InChIKey=PHLYOKFVXIVOJC-UHFFFAOYSA-N

InChI=1S/C20H12O7/c21-13-7-5-11-17(15(13)23)26-18-12(6-8-14(22)16(18)24)20(11)10-4-2-1-3-9(10)19(25)27-20/h1-8,21-24H

HIDE SMILES / InChI

Molecular Formula	C20H12O7
Molecular Weight	364.3051
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18006643 | https://www.ncbi.nlm.nih.gov/pubmed/4142135 | https://www.ncbi.nlm.nih.gov/pubmed/18006643 | http://www.fasebj.org/content/29/1_Supplement/618.4 | https://www.ncbi.nlm.nih.gov/pubmed/22552300 | https://www.ncbi.nlm.nih.gov/pubmed/29084601

Gallein is an inhibitor of G protein beta gamma subunit signaling. It exerts antineoplastic action in vitro and anti-inflammatory action in vivo. Gallein may be used in histological staining.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
G-protein beta/gamma-subunit complex 2 Target ID: GO:0031680 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18006643	Inhibitor 8504		422.0 nM [Kd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Inflammation 105 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18006643 http://www.fasebj.org/content/29/1_Supplement/618.4	Primary		Preclinical	Unknown Approved Use Unknown
Cancer 609 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22552300 https://www.ncbi.nlm.nih.gov/pubmed/29084601	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Inhibition of Gβγ-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward.	2013-04	23412114
Identification of HIV-1 nucleocapsid protein: nucleic acid antagonists with cellular anti-HIV activity.	2002-09-06	12207905
Specificity in structure-based drug design: identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase.	1997-09	9294866
Staining myelin in brain with gallein: a new method.	1977-09	73233
Hematoxylin substitutes: gallein as a biological stain.	1974-11	4142135

Sample Use Guides

In Vivo Use Guide

Oral administration of gallein (30 mg/kg) inhibited paw edema and neutrophil infiltration in a mouse carrageenan-induced paw edema model.

Route of Administration: Oral

In Vitro Use Guide

Gallein 10 uM was able to significantly counteract this β-ionone-induced LNCaP cell invasiveness.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:50:58 GMT 2025` Edited by `admin` on `Mon Mar 31 21:50:58 GMT 2025`
Record UNII	8L0084U2QR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GALLEIN

Common Name

English

C.I.- 45445

Preferred Name

English

NSC-622478

Code

English

NSC-56445

Code

English

MORDANT VIOLET 25

Common Name

English

C.I. MORDANT VIOLET 25

Common Name

English

PYROGALLOLPHTHALEIN

Common Name

English

NSC-8668

Code

English

GALLEIN [MI]

Common Name

English

SPIRO(ISOBENZOFURAN-1(3H),9'-(9H)XANTHEN)-3-ONE, 3',4',5',6'-TETRAHYDROXY-

Systematic Name

English

Code System Code Type Description

NSC

622478